Table 4.

Schematic representation of HRD score evaluated by each participating institution by using commercially available NGS assays on a retrospective series of diagnostic HGSOC specimens

Sample ID	Centre #1		Centre #2	Centre #3
	Illumina NextSeq 550Dx	Illumina HiSeq 2500	Ion Gene Studio S5 Plus System	Illumina NextSeq 550 platform
	SOPHiA DDM HRD solution panel	MyChoice CDx Myriad HRD	Oncomine HRR pathway panel	Amoy HRD focus panel
ID_1	POS	NEG	POS*	POS
ID_2	POS	POS	NEG	POS
ID_3	POS	POS	POS	POS
ID_4	NEG	POS	POS	POS
ID_5	NEG	NEG	NEG	NEG
ID_6	NEG	NEG	NEG	NEG
ID_7	NEG	NEG	NEG	NEG
ID_8	NEG	NEG	NEG	NEG
ID_9	NEG	NEG	NEG	NEG
ID_10	NEG	NEG	NEG	NA
ID_11	POS	POS	NEG	NA
ID_12	NEG	NEG	NEG	NEG
ID_13	POS	POS	NEG	POS
ID_14	NEG	NEG	NEG	NEG
ID_15	NEG	NEG	NEG	NEG
ID_16	POS	POS	POS	POS
ID_17	NEG	NEG	NEG	POS*
ID_18	NEG	NEG	NEG	NA
ID_19	POS	POS	POS	POS
ID_20	NEG	NEG	NEG	NEG

*Borderline results.

HRD, homologous recombination deficiency; HRR, homologous recombination repair; ID, identify number; NA, not assessed; NEG, negative; NGS, next-generation sequencing; POS, positive.